ImmunoCellular Therapeutics Ltd


Company Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Names Anthony Gringeri CEO

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of …

Company Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Announces One-for-Forty Reverse Stock Split

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016, ImmunoCellular’s stockholders voted to approve a …

Stock Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Reports 3Q:16 Results and Provides Research and Development Update

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the third quarter of 2016 and provided an update on its research and development activities. Andrew …

Company Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Announces Second Quarter 2016 Financial Results

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the second quarter of 2016. Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: “We are pleased …

Company Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Announces Pricing of $7.4 Million Public Offering

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the pricing of an underwritten public offering of 47,000,000 shares of its common stock and base warrants to …

Company Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Reports Progress in Two Lead Cancer Immunotherapy Programs

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly …

Stock Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company’s lead …

Stock Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Announces First Quarter 2016 Financial Results

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the first quarter of 2016. Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: “We continue to …

Company Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology …

Stock Update (NYSEMKT:IMUC): ImmunoCellular Therapeutics Ltd Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium (CBTC), for the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts